BLA 761326 · Novo Nordisk INC
Awiqli Flextouch
Insulin Icodec · Solution
NovelOrphanLast checked: Nov 20, 2026Latest source record: Oct 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Mar 26, 2026
Approved uses
2
Original approval plus efficacy supplements
Registered trials
36
15 Phase 3, 6 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 23, 2026 Supplement 1 · Efficacy · priority review LetterLabel
- Mar 26, 2026 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
1 products under this application
- AWIQLI FLEXTOUCH · INSULIN ICODEC · INJECTION, SOLUTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Insulin Icodec" as an intervention, any sponsor and status, largest first.
- A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin IcodecPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05352815 · 1,291 participants · Start Jun 1, 2022 · Primary completion Mar 19, 2024
Drug: IcoSema; Insulin icodec · For: Diabetes Mellitus, Type 2
Sites: Gilbert, Arizona; Glendale, Arizona; Phoenix, Arizona · 281 sites in all
- A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin BeforePivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT04760626 · 1,085 participants · Start Mar 1, 2021 · Primary completion Aug 12, 2022
Drug: Insulin icodec; Insulin Glargine 100U/mL and 2 more · For: Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Guntersville, Alabama; Gilbert, Arizona · 311 sites in all
- A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin BeforePivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT04460885 · 984 participants · Start Nov 25, 2020 · Primary completion May 29, 2022
Drug: Insulin icodec; Insulin glargine · For: Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Guntersville, Alabama; Little Rock, Arkansas · 198 sites in all
- A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 DiabetesPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07076199 · 877 participants (planned) · Start Aug 11, 2025 · Primary completion Jan 25, 2027
Drug: Insulin icodec; Insulin glargine and 1 more · For: Diabetes Mellitus, Type 1
Sites: Cullman, Alabama; Concord, California; Escondido, California · 182 sites in all
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05259033 · 683 participants · Start Apr 11, 2022 · Primary completion Dec 13, 2023
Drug: IcoSema; Semaglutide 1 mg · For: Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Gilbert, Arizona; Phoenix, Arizona · 193 sites in all
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05013229 · 679 participants · Start Nov 30, 2021 · Primary completion Nov 14, 2023
Drug: IcoSema; Insulin glargine and 1 more · For: Diabetes Mellitus, Type 2
Sites: Guntersville, Alabama; Fresno, California; La Jolla, California · 182 sites in all
- A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)Pivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT04795531 · 588 participants · Start Mar 24, 2021 · Primary completion Jun 23, 2022
Drug: Insulin icodec; Placebo insulin icodec and 2 more · For: Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Guntersville, Alabama; Little Rock, Arkansas · 190 sites in all
- A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 DiabetesPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07112339 · 586 participants (planned) · Start Aug 15, 2025 · Primary completion Mar 23, 2028
Drug: Insulin icodec; Basal insulin analogues · For: Diabetes Mellitus, Type 2
Sites: Calgary, Canada; Edmonton, Canada; New Westminster, Canada · 75 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial.
Lingvay I, Asong M, Desouza C, et al. · JAMA 2023 · Clinical Trial, Phase III, Equivalence Trial
- Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
Rosenstock J, Bain SC, Gowda A, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Comparative Study
- Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial.
Philis-Tsimikas A, Asong M, Franek E, et al. · Lancet Diabetes Endocrinol 2023 · Randomized Controlled Trial, Multicenter Study
- Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.
Mathieu C, Ásbjörnsdóttir B, Bajaj HS, et al. · Lancet 2023 · Randomized Controlled Trial, Multicenter Study
- Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized Trial.
Bajaj HS, Aberle J, Davies M, et al. · Ann Intern Med 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
- Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial.
Russell-Jones D, Babazono T, Cailleteau R, et al. · Lancet 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Novo Nordisk
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.